Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs

Vaccine

Volumn 28, Issue 6, 2010, Pages 1583-1593

  Senger, Tilo ^a   Schädlich, Lysann ^a   Textor, Sonja ^a   Klein, Corinna ^a   Michael, Kristina M ^a   Buck, Christopher B ^b   Gissmann, Lutz ^a,c  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b NATIONAL CANCER INSTITUTE   (United States)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Capsomeres; Cutaneous; Immunogenicity; Papillomavirus; Prophylactic vaccine; Virus like particle

Indexed keywords

A 8222; ALUMINUM HYDROXIDE; CALGRANULIN; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; WART VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CAPSOMERE; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS REACTION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 2; HUMAN PAPILLOMAVIRUS TYPE 27; HUMAN PAPILLOMAVIRUS TYPE 57; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; VERRUCA VULGARIS; VIRUS CAPSID; VIRUS LIKE AGENT; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ALPHAPAPILLOMAVIRUS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID; CAPSID PROTEINS; CROSS REACTIONS; INTERFERON-GAMMA; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; SKIN DISEASES, VIRAL; T-LYMPHOCYTES; VACCINES, VIROSOME; VIROSOMES; WARTS;

EID: 75249106732     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.11.048     Document Type: Article

References (66)

1. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 1 (2004) 17-27
2. Pass F., Reissig M., Shah K.V., Eisinger M., and Orth G. Identification of an immunologically distinct papillomavirus from lesions of epidermodysplasia verruciformis. J Natl Cancer Inst 59 4 (1977) 1107-1112
3. Jablonska S., and Majewski S. Epidermodysplasia verruciformis: immunological and clinical aspects. Curr Top Microbiol Immunol 186 (1994) 157-175
4. Nindl I., Gottschling M., and Stockfleth E. Human papillomaviruses and non-melanoma skin cancer: basic virology and clinical manifestations. Dis Markers 23 4 (2007) 247-259
5. Majewski S., and Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 131 11 (1995) 1312-1318
6. Michel A., Kopp-Schneider A., Zentgraf H., Gruber A.D., and de Villiers E.M. E6/E7 expression of human papillomavirus type 20 (HPV-20) and HPV-27 influences proliferation and differentiation of the skin in UV-irradiated SKH-hr1 transgenic mice. J Virol 80 22 (2006) 11153-11164
7. Jablonska S., Majewski S., Obalek S., and Orth G. Cutaneous warts. Clin Dermatol 15 3 (1997) 309-319
8. Gassenmaier A., Fuchs P., Schell H., and Pfister H. Papillomavirus DNA in warts of immunosuppressed renal allograft recipients. Arch Dermatol Res 278 3 (1986) 219-223
9. Stockfleth E., Nindl I., Sterry W., Ulrich C., Schmook T., and Meyer T. Human papillomaviruses in transplant-associated skin cancers. Dermatol Surg 30 4 Pt 2 (2004) 604-609
10. Dyall-Smith D., Trowell H., and Dyall-Smith M.L. Benign human papillomavirus infection in renal transplant recipients. Int J Dermatol 30 11 (1991) 785-789
11. Harwood C.A., Spink P.J., Surentheran T., Leigh I.M., de Villiers E.M., McGregor J.M., et al. Degenerate and nested PCR: a highly sensitive and specific method for detection of human papillomavirus infection in cutaneous warts. J Clin Microbiol 37 11 (1999) 3545-3555
12. Duchini A., Goss J.A., Karpen S., and Pockros P.J. Vaccinations for adult solid-organ transplant recipients: current recommendations and protocols. Clin Microbiol Rev 16 3 (2003) 357-364
13. Müller M., and Gissmann L. A long way: history of the prophylactic papillomavirus vaccine. Dis Markers 23 4 (2007) 331-336
14. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89 24 (1992) 12180-12184
15. Christensen N.D., Hopfl R., DiAngelo S.L., Cladel N.M., Patrick S.D., Welsh P.A., et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 75 Pt 9 (1994) 2271-2276
16. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
17. Kirnbauer R., Taub J., Greenstone H., Roden R., Durst M., Gissmann L., et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67 12 (1993) 6929-6936
18. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
19. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 11 (2006) 1459-1466
20. Hagensee M.E., Yaegashi N., and Galloway D.A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67 1 (1993) 315-322
21. Sasagawa T., Pushko P., Steers G., Gschmeissner S.E., Hajibagheri M.A., Finch J., et al. Synthesis and assembly of virus-like particles of human papillomaviruses type 6 and type 16 in fission yeast Schizosaccharomyces pombe. Virology 206 1 (1995) 126-135
22. Rose R.C., Reichman R.C., and Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75 Pt 8 (1994) 2075-2079
23. Fligge C., Giroglou T., Streeck R.E., and Sapp M. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology 283 2 (2001) 353-357
24. Dell K., Koesters R., Linnebacher M., Klein C., and Gissmann L. Intranasal immunization with human papillomavirus type 16 capsomeres in the presence of non-toxic cholera toxin-based adjuvants elicits increased vaginal immunoglobulin levels. Vaccine 24 13 (2006) 2238-2247
25. Yuan H., Estes P.A., Chen Y., Newsome J., Olcese V.A., Garcea R.L., et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 75 17 (2001) 7848-7853
26. Senger T., Schadlich L., Gissmann L., and Muller M. Enhanced papillomavirus-like particle production in insect cells. Virology 388 2 (2009) 344-353
27. Fitzgerald D.J., Berger P., Schaffitzel C., Yamada K., Richmond T.J., and Berger I. Protein complex expression by using multigene baculoviral vectors. Nat Methods 3 12 (2006) 1021-1032
28. Berger I., Fitzgerald D.J., and Richmond T.J. Baculovirus expression system for heterologous multiprotein complexes. Nat Biotechnol 22 12 (2004) 1583-1587
29. Matsuura Y., Possee R.D., Overton H.A., and Bishop D.H. Baculovirus expression vectors: the requirements for high level expression of proteins, including glycoproteins. J Gen Virol 68 Pt 5 (1987) 1233-1250
30. Müller M., Zhou J., Reed T.D., Rittmüller C., Burger A., Gabelsberger J., et al. Chimeric papillomavirus-like particles. Virology 234 1 (1997) 93-111
31. Sapp M., Fligge C., Petzak I., Harris J.R., and Streeck R.E. Papillomavirus assembly requires trimerization of the major capsid protein by disulfides between two highly conserved cysteines. J Virol 72 7 (1998) 6186-6189
32. Li M., Beard P., Estes P.A., Lyon M.K., and Garcea R.L. Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J Virol 72 3 (1998) 2160-2167
33. Chen X.S., Casini G., Harrison S.C., and Garcea R.L. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol 307 1 (2001) 173-182
34. Schädlich L., Senger T., Kirschning C.J., Müller M., and Gissmann L. Refining HPV 16 L1 purification from E. coli: Reducing endotoxin contaminations and their impact on immunogenicity. Vaccine 27 10 (2009) 1511-1522
35. Waterboer T., Sehr P., Michael K.M., Franceschi S., Nieland J.D., Joos T.O., et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 51 10 (2005) 1845-1853
36. Waterboer T., Sehr P., and Pawlita M. Suppression of non-specific binding in serological Luminex assays. J Immunol Methods 309 1-2 (2006) 200-204
37. Michael K.M., Waterboer T., Sehr P., Rother A., Reidel U., Boeing H., et al. Seroprevalence of 34 human papillomavirus types in the German general population. PLoS Pathog 4 6 (2008) e1000091
38. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J Virol 78 2 (2004) 751-757
39. Tannous B.A., Kim D.E., Fernandez J.L., Weissleder R., and Breakefield X.O. Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11 3 (2005) 435-443
40. Buck C.B., Thompson C.D., Roberts J.N., Muller M., Lowy D.R., and Schiller J.T. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2 7 (2006) e69
41. Chan S.Y., Chew S.H., Egawa K., Grussendorf-Conen E.I., Honda Y., Rubben A., et al. Phylogenetic analysis of the human papillomavirus type 2 (HPV-2), HPV-27, and HPV-57 group, which is associated with common warts. Virology 239 2 (1997) 296-302
42. Öhlschläger P., Osen W., Dell K., Faath S., Garcea R.L., Jochmus I., et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 77 8 (2003) 4635-4645
43. Thönes N., Herreiner A., Schädlich L., Piuko K., and Müller M. A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response. J Virol 82 11 (2008) 5472-5485
44. Schädlich L., Senger T., Gerlach B., Mücke N., Klein C., Bravo I.G., et al. Analysis of modified human papillomavirus type 16 L1 capsomeres: the ability to assemble into larger particles correlates with higher immunogenicity. J Virol 83 15 (2009) 7690-7705
45. Smith J.F., Kowalski R., Esser M.T., Brown M.J., and Bryan J.T. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11. Hum Vaccin 4 2 (2008) 134-142
46. Rizk R.Z., Christensen N.D., Michael K.M., Muller M., Sehr P., Waterboer T., et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 89 Pt 1 (2008) 117-129
47. Carter J.J., Wipf G.C., Benki S.F., Christensen N.D., and Galloway D.A. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol 77 21 (2003) 11625-11632
48. Christensen N.D., Cladel N.M., Reed C.A., Budgeon L.R., Embers M.E., Skulsky D.M., et al. Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291 2 (2001) 324-334
49. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76 13 (2002) 6480-6486
50. Culp T.D., Spatz C.M., Reed C.A., and Christensen N.D. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 361 2 (2007) 435-446
51. McClements W.L., Wang X.M., Ling J.C., Skulsky D.M., Christensen N.D., Jansen K.U., et al. A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology 289 2 (2001) 262-268
52. Ludmerer S.W., Benincasa D., Mark III G.E., and Christensen N.D. A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol 71 5 (1997) 3834-3839
53. Ludmerer S.W., McClements W.L., Wang X.M., Ling J.C., Jansen K.U., and Christensen N.D. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology 266 2 (2000) 237-245
54. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
55. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; Types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-Naive women aged 16-26 years. J Infect Dis 199 7 (2009) 926-935
56. Handisurya A., Gambhira R., Schellenbacher C., Shafti-Keramat S., Forslund O., Favre M., et al. Serological relationship between cutaneous human papillomavirus types 5, 8, and 92. J Gen Virol 90 Pt 1 (2009) 136-143
57. Senger T., Becker M.R., Schadlich L., Waterboer T., and Gissmann L. Identification of B-cell epitopes on virus-like particles of cutaneous alpha-human papillomaviruses. J Virol 83 24 (2009) 12692-12701
58. Ruiz W., McClements W.L., Jansen K.U., and Esser M.T. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16, and 18 L1-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccine 3 1 (2005) 2
59. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24 33-34 (2006) 5937-5949
60. Lowe R.S., Brown D.R., Bryan J.T., Cook J.C., George H.A., Hofmann K.J., et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176 5 (1997) 1141-1145
61. Thönes N., and Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 369 2 (2007) 375-388
62. Garcia-Pineres A., Hildesheim A., Dodd L., Kemp T.J., Williams M., Harro C., et al. Cytokine and chemokine profiles following vaccination with human papillomavirus type 16 L1 virus-like particles. Clin Vaccine Immunol 14 8 (2007) 984-989
63. Pinto L.A., Castle P.E., Roden R.B., Harro C.D., Lowy D.R., Schiller J.T., et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine responses in whole blood. Vaccine 23 27 (2005) 3555-3564
64. Trollfors B., Taranger J., Lagergard T., and Sundh V. Reduced immunogenicity of diphtheria and tetanus toxoids when combined with pertussis toxoid. Pediatr Infect Dis J 24 1 (2005) 85-86
65. Sun W., Nisalak A., Gettayacamin M., Eckels K.H., Putnak J.R., Vaughn D.W., et al. Protection of Rhesus monkeys against dengue virus challenge after tetravalent live attenuated dengue virus vaccination. J Infect Dis 193 12 (2006) 1658-1665
66. Garland S.M., Steben M., Hernandez-Avila M., Koutsky L.A., Wheeler C.M., Perez G., et al. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 14 6 (2007) 792-795